Pharmafile Logo

News and Press Releases

Symeres and Ambagon Therapeutics collaborate on molecular glue research in colorectal cancer

31 March 2026 -- Nijmegen, Netherlands -- Symeres, a leading CRDMO for drug discovery and development has partnered with Ambagon Therapeutics, a pre-clinical biotechnology company, to explore a new class...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2026

Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland

Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: March 31, 2026

Samsung Biologics
300, Songdo bio-daero, Yeonsu-gu, Incheon, Republic of Korea

Johnson & Johnson’s DARZALEX (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma Milestone is a testament to ten years of daratumumab experience and innovation, continuing...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: March 27, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Lonza Launches Media Development Lab in Singapore for Cell Culture Media Optimisation

New media development services designed to optimize cell culture media development and identify robust, scalable media formulations driving cell culture performance and reliability The offering is designed to improve performance,...

Category: BioManufacturing, Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2026

Lonza
Muenchensteinerstrasse 38 Basel, 4002

Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards

• Reinforcing long-term commitment to embedding sustainability across operations and partnerships• Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide. 16 March 2026 -- Incheon, South Korea...

Category: BioManufacturing, Other, Pharmaceutical
Posted: March 16, 2026

Samsung Biologics
300, Songdo bio-daero, Yeonsu-gu, Incheon, Republic of Korea

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance. 10 March...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

Medidata Expands Partnership with The Menarini Group, Deploying Medidata’s Study Build AI Technology to Accelerate Global Oncology Pipeline

Fourteen-year collaboration enters a new phase as Menarini evolves its use of the Medidata Platform, combining established clinical workflows with AI to power its global oncology pipeline 9 March 2026...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

European Commission approves AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles 26 February 2026 -- Massachusetts, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 3, 2026

Curium Pharma
contactus@curiumpharma.com
Perceptive 55 Blue Sky Drive Burlington Massachusetts 01803 United States

Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening

• Drs Giulia Kennedy, Arnold Levine, John Sninsky, Martin Goldberg and Prof Tin Tin Su join SAB• Follows close of initial funding round with investment from Stephen Quake and Jay...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 2, 2026

Wisdom Bioscience
info@wisdombioscience.com

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 26, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California

24 February 2026 -- California, US -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state of...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: February 24, 2026

Avid Bioservices
14191 Myford Road Tustin, California 92780

NICE Recommends TEPKINLY▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy

Epcoritamab can now be accessed as an option to treat relapsed or refractory follicular lymphoma in adults after 2 or more lines of systemic treatment, only if epcoritamab is stopped...

Category: Drug Discovery, Other, Pharmaceutical
Posted: February 23, 2026

AbbVie
AbbVie House Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026

9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose 17 February 2026 -- Oslo, Norway -- Oncoinvent, a biotech...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026

Oncoinvent
oncoinvent@oncoinvent.com
Gullhaugveien 7 0484 Oslo Norway

Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)

17 February 2026 -- Oslo, Norway -- Lytix Biopharma AS, a clinical-stage immuno-oncology company, today announced the publication of a review article in the Journal of ImmunoTherapy of Cancer (JITC)....

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026

Lytix Biopharma
post@lytixbiopharma.com
Sandakerveien 138, 0484 Oslo, Norway